Clinical Trial Update: Open-label Clinical Trial to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates for Immune Reconstitution After Allogeneic Stem Cell Transplantation Measured as Response to a Antedated Single Vaccination [Phase 1, Phase 2]

View source ↗

Summary

Open-label Phase 1/2 clinical trial evaluating the safety and tolerability of donor-derived allogeneic B-cell concentrates to support immune reconstitution afte…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Aplastic Anemia
• Chronic Myeloid Leukemia
• Hodgkin Lymphoma
• Multiple Myeloma
• Myelodysplastic Syndrome
• Non-hodgkin Lymphoma

Drugs mentioned

• Allogeneic B-cell concentrates (Allogeneic B-cell concentrates)

Snippet

Sponsor: University of Erlangen-Nürnberg Medical School | Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 1, Phase 2 | Status: UNKNOWN